Y-3 Injection in the Treatment of Acute Ischemic Stroke Phase II Clinical Trial

Inclusion Criteria:

• Only those who meet all the following criteria can be included in the group:

1. Age ≥ 18 years old and<81 years old, regardless of gender;

2. After the onset of this disease, the National Institutes of Research Stroke Scalescore was 6 ≤ NIHSS ≤ 20 points, and the sum of the 5th upper limb and 6th lowerlimb scores was ≥ 2 points. If patients receiving thrombolysis treatment werescreened and evaluated based on the NIHSS score after thrombolysis;

3. Within 48 hours (including 48 hours) of onset;

4. Diagnosed as ischemic stroke according to the "Key Diagnostic Points for VariousMajor Cerebrovascular Diseases in China 2019", with good recovery after the first orlast onset (mRS score ≤ 1 point before this onset);

5. Obtain informed consent from the patient or their legal representative voluntarilysigned and approved by the ethics committee.

Exclusion Criteria:

• Those who meet one of the following criteria during filtering cannot be included in the group:

1. Intracranial hemorrhagic diseases seen on cranial imaging: hemorrhagic stroke,epidural hematoma, intracranial hematoma, ventricular hemorrhage, subarachnoidhemorrhage, etc; If it is only oozing blood, the researcher can determine whether itis suitable for enrollment;

2. Severe consciousness disorder: The item score of NIHSS's 1a consciousness level isgreater than 1 point;

3. Transient ischemic attack (TIA);

4. After controlling the patient's blood pressure, the systolic blood pressure remains ≥ 220mmHg or the diastolic blood pressure remains ≥ 120mmHg;

5. Previously diagnosed patients with severe mental disorders and severe dementia;

6. Patients previously diagnosed with depression or anxiety disorder;

7. Patients undergoing antidepressant or anti anxiety treatment;

8. Diagnosed with severe active liver diseases, such as acute hepatitis, chronic activehepatitis, liver cirrhosis, etc; Or ALT or AST>2.0 × ULN;

9. Diagnosed with severe active kidney disease or renal insufficiency; Or serumcreatinine>1.5 × ULN;

10. After the onset of the disease, drugs with brain cytoprotection in the instructionshave been used, such as edaravone, concentrated solution of edaravone and dextranolfor injection, nimodipine, ganglioside, CDPC, piracetam, oxiracetam,butylphenylpeptide, human urinary kallidinogenase (Urinary Kallidinogenase),cinepazide, rat nerve growth factor, cerebrolysin (cerebroprotein hydrolysate), calfserum deproteinized injection Calf blood deproteinized extract injection, etc;

11. After the onset of this disease, thrombectomy or interventional therapy has beenapplied or planned to be applied;

12. Previously diagnosed with concurrent malignant tumors and undergoing anti-tumortreatment;

13. Previously diagnosed with severe systemic diseases, with an estimated survivalperiod of<90 days;

14. The patient is in pregnancy, lactation, and there is a possibility of pregnancy inthe patient/patient partner who plans to conceive during the trial period;

15. Previously known allergies to this product or any of its excipients (15-hydroxystearic acid polyethylene glycol ester, propylene glycol, sodiumhydroxide);

16. A history of major surgeries within 4 weeks prior to enrollment and assessed by theresearcher as affecting neurological function scores or affecting 90 day survival;

17. Have participated in other clinical studies or are currently participating in otherclinical studies within the first 30 days of randomization;

18. The researcher believes that it is not suitable to participate in this clinicalstudy.